Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...

Thinking about learning Python? It’s a pretty popular language these days, and for good reason. It’s not super complicated, which is nice if you’re just starting out. We’ve put together a guide that ...

What if you could create your very own personal AI assistant—one that could research, analyze, and even interact with tools—all from scratch? It might sound like a task reserved for seasoned ...

NEW YORK, NY / ACCESS Newswire / July 30, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc.("Replimune" or the "Company")(NASDAQ:REPL). Such ...

Recent discussions on X about Replimune Group Inc. (REPL) have been ignited by the U.S. FDA's rejection of the company's lead drug, RP1, for melanoma treatment in combination therapy. Many users are ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...